Capstone Investment Advisors LLC bought a new position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,123 shares of the biotechnology company’s stock, valued at approximately $608,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Redwood Investment Management LLC purchased a new position in United Therapeutics during the second quarter valued at approximately $1,167,000. Proficio Capital Partners LLC purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $438,000. Transamerica Financial Advisors LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $187,000. Corient Private Wealth LP acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $8,443,000. Finally, Artia Global Partners LP purchased a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $2,709,000. 94.08% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $541.39, for a total value of $5,143,205.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,933,333.07. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 424,075 shares of company stock valued at $227,336,485. 8.60% of the stock is currently owned by insiders.
United Therapeutics Price Performance
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the company earned $6.41 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the stock. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $646.00.
Check Out Our Latest Research Report on UTHR
United Therapeutics Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
